Table 1 Basic characteristics of all participants
Variables | RRMM (n = 71) | MM (n = 70) | Healthy (n = 70) | p1 | p2 |
|---|---|---|---|---|---|
Age (year) | 63 (48–76) | 64.5 (49–76) | 61.5 (48–75) | 0.554 | 0.292 |
Sex (male, %) | 48 (67.61) | 43 (61.43) | 45 (64.29) | 0.361 | 0.620 |
BMI (kg/m2) | 21.87 ± 3.70 | 22.32 ± 3.29 | 21.98 ± 3.42 | 0.436 | 0.847 |
ISS stage (n, %) | 0.750 | ||||
I | 14 (19.72) | 16 (22.86) | – | ||
II | 24 (33.80) | 25 (35.71) | |||
III | 33 (46.48) | 29 (41.43) | |||
Disease course (mon) | 7 (5–9) | – | – | ||
Ig type (n, %) | 0.511 | ||||
IgG | 41 (57.75) | 34 (48.57) | – | ||
IgA | 11 (15.49) | 16 (22.86) | |||
IgM | 0 (0) | 0 (0) | |||
Light chain λ | 10 (14.08) | 10 (14.29) | |||
Light chain κ | 9 (12.68) | 10 (14.29) | |||
Mediations used before (n, %) | |||||
Lenalidomide | 35 (49.30) | – | – | ||
Dexamethasone | 59 (83.10) | ||||
Bortezomib | 40 (56.34) | ||||
Adriamycin | 12 (16.90) | ||||
1-year mortality (n, %) | 12 (16.90) | 4 (5.71) | – | 0.012 | – |